ANNX
Annexon, Inc.
$3.75
-1.57%
2026-10-23
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Key Fundamentals
Forward P/E
-3.36
EPS (TTM)
$-1.13
ROE
-105.3%
Profit Margin
0.0%
Debt/Equity
13.25
Price/Book
3.41
Beta
1.22
Market Cap
$690.1M
Avg Volume (10D)
3.3M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$5.70
60D Low
$3.35
Avg Volume
3.1M
Latest Close
$3.75
Get breakout alerts for ANNX
Sign up for Breakout Scanner to receive daily notifications when ANNX triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Annexon, Inc. (ANNX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ANNX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ANNX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.